A new trading day began on Friday, with ARS Pharmaceuticals Inc (NASDAQ: SPRY) stock price up 4.63% from the previous day of trading, before settling in for the closing price of $13.38. SPRY’s price has ranged from $4.65 to $18.51 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -34.76%. Meanwhile, its annual earnings per share averaged 12.72%. With a float of $50.74 million, this company’s outstanding shares have now reached $96.41 million.
Let’s determine the extent of company efficiency that accounts for 26 employees. In terms of profitability, gross margin is 93.97%, operating margin of -2384.0%, and the pretax margin is -1934.75%.
ARS Pharmaceuticals Inc (SPRY) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of ARS Pharmaceuticals Inc is 47.89%, while institutional ownership is 42.07%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,394,960. In this transaction PRESIDENT AND CEO of this company sold 100,000 shares at a rate of $13.95, taking the stock ownership to the 1,198,499 shares. Before that another transaction happened on Nov 19 ’24, when Company’s CHIEF MEDICAL OFFICER sold 100,000 for $13.95, making the entire transaction worth $1,394,960. This insider now owns 1,198,499 shares in total.
ARS Pharmaceuticals Inc (SPRY) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.07 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.72% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Here are ARS Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 12.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 553.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Looking closely at ARS Pharmaceuticals Inc (NASDAQ: SPRY), its last 5-days average volume was 1.02 million, which is a jump from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 11.48%. Additionally, its Average True Range was 1.03.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 53.29%, which indicates a significant increase from 18.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.95% in the past 14 days, which was higher than the 72.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.78, while its 200-day Moving Average is $10.97. However, in the short run, ARS Pharmaceuticals Inc’s stock first resistance to watch stands at $14.28. Second resistance stands at $14.55. The third major resistance level sits at $15.07. If the price goes on to break the first support level at $13.49, it is likely to go to the next support level at $12.97. Now, if the price goes above the second support level, the third support stands at $12.70.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
With a market capitalization of 1.42 billion, the company has a total of 97,185K Shares Outstanding. Currently, annual sales are 30 K while annual income is -54,370 K. The company’s previous quarter sales were 2,070 K while its latest quarter income was -19,130 K.
